Huawe Medicine

Huawe Medicine, officially Nanjing Huawe Pharmaceutical Technology Co., Ltd., is a leading Chinese contract research organization (CRO) and drug development firm. Founded in 2000 and headquartered in Nanjing, the company provides comprehensive R&D services including drug discovery, CMC, preclinical studies, and clinical trial management. Huawe specializes in high-end generic drugs and innovative small molecules, with a portfolio spanning oncology, cardiovascular, and metabolic therapeutic areas. In 2016, the company was acquired by Hainan Haiyao, a move that bolstered its manufacturing and commercialization capabilities. Huawe is recognized for its extensive track record in securing regulatory approvals from the National Medical Products Administration (NMPA). The company has successfully developed and transferred hundreds of drug technologies to various pharmaceutical manufacturers across China.